EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Ligandability assessment of interferonopathy‐associated proteins using chemoproteomics

Nathan M Alba, Carys R Jones, Ffion L Jones, Lyn H Jones

British Journal of Pharmacology · 2026-11 · 183 (22) · 6649-6655

DOI: 10.1111/bph.70256 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2025-11-12. Written by Nathan M Alba and 3 co-authors. Institution: Burlington High School, Burlington, Massachusetts, USA. Major MEDLINE topics: Proteomics, Interferons, Autoimmune Diseases. Cited 2 times so far (Crossref); 30 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Mendelian type I interferonopathies are autoimmune diseases caused by genetic mutations that result in upregulation of interferon signalling. Small molecules that modulate proteins encoded by these genes may drive anti‐tumour immunity in cancer patients by increasing interferon levels, but chemical probes and drugs are lacking. Covalent chemoproteomics and structural data were compiled to reveal ligandable cysteines, tyrosines and lysines across diverse proteins associated with interferonopathies. From this analysis, we identified several actionable targets, including ligandable sites on ADAR1, RNASEH2A and SAMHD1, and so our work provides a useful resource for future drug discovery efforts directed towards the development of immunotherapeutics. LINKED ARTICLES This article is part of a themed issue Re‐emergence of Covalent Modulation in Drug Discovery. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.22/issuetoc

Subjects

MeSH terms (MEDLINE)

ProteomicsInterferonsAutoimmune DiseasesHumansLigandsAnimalsDrug Discovery

Author keywords

chemoproteomicscovalent inhibitordrug discoveryinterferonopathyligandability

Substances

LigandsInterferons

Authors and institutions

  • Burlington High School, Burlington, Massachusetts, USA.
  • Winchester High School, Winchester, Massachusetts, USA.
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

Cite

APA

Alba, N. M., Jones, C. R., Jones, F. L., & Jones, L. H. (2026). Ligandability assessment of interferonopathy‐associated proteins using chemoproteomics. British Journal of Pharmacology, 183(22), 6649-6655. https://doi.org/10.1111/bph.70256

Vancouver

Alba NM, Jones CR, Jones FL, Jones LH. Ligandability assessment of interferonopathy‐associated proteins using chemoproteomics. British Journal of Pharmacology. 2026;183(22):6649-6655. doi:10.1111/bph.70256

BibTeX
@article{Alba2026,
  author = {Alba, Nathan M and Jones, Carys R and Jones, Ffion L and Jones, Lyn H},
  title = {Ligandability assessment of interferonopathy‐associated proteins using chemoproteomics},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {22},
  pages = {6649--6655},
  doi = {10.1111/bph.70256}
}
Start for free →